Figure 2.
Mutations in myeloid and T lymphocyte compartments in MDS patients considered short-survivors and long-survivors treated with guadecitabine and atezolizumab
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.